Legal & General Group
CLYM

Legal & General Group’s Climb Bio CLYM Stock Holding History

Legal & General Group’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,581
Closed -$3.16K – 3575
2025
Q1 		$3.16K Hold
2,581
– – ﹤0.01% 3327
2024
Q4 		$4.63K Hold
2,581
– – ﹤0.01% 3341
2024
Q3 		$13.1K Buy
2,581
+1,950
+309% +$13.8K ﹤0.01% 3207
2024
Q2 		$4.52K Buy
+631
New +$4.2K ﹤0.01% 3384
2022
Q3 		– Sell
-560
Closed -$2K – 3496
2022
Q2 		$2K Sell
560
-99
-15% -$468 ﹤0.01% 3493
2022
Q1 		$5K Hold
659
– – ﹤0.01% 3512
2021
Q4 		$7K Hold
659
– – ﹤0.01% 3526
2021
Q3 		$12K Buy
+659
New +$13.6K ﹤0.01% 3424

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

Legal & General Group's CLYM Position: Q2 2025 in Review

Legal & General Group sold out of Climb Bio (CLYM) in Q2 2025, closing a stake of 2,581 shares — an estimated $3.16K sold.

Legal & General Group first reported a position in CLYM in Q3 2021 and held it in 8 quarters. The position peaked at $13.1K in Q3 2024. 69 funds tracked by Wall St. Rank hold CLYM as of Q2 2025.

  • Legal & General Group reported no remaining Climb Bio position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 2,581 Climb Bio shares in Q2 2025, an estimated $3.16K.
  • Legal & General Group first reported a position in Climb Bio in Q3 2021 and held it in 8 quarters.
  • Legal & General Group's Climb Bio position peaked at $13.1K in Q3 2024.
  • 69 funds tracked by Wall St. Rank held Climb Bio as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.